Framingham, MA – DPS Group announced it has expanded its U.S. headquarters at 959 Concord Street in Framingham to accommodate and serve the needs of its clients in an expanding market.
Founded in 1974 in Dublin, Ireland, to service the country’s burgeoning pharmaceutical sector, DPS Group opened its first office in the U.S. in 2011 with a staff of less than 10 based in Framingham. The company has since grown its U.S. presence to over 900 employees across eight offices in Albany, N.Y.; Cary, N.C.; Framingham, Mass.; Portland, Ore.; Kansas City, Kan.; Philadelphia, Pa.; Phoenix, Ariz.; and Wall Township, N.J.
“Over the past 10 years, our Boston client roster has grown year over year, and we continue to recruit talented staff to address the need for highly specialized design in the life science and biotech industries,” said Paul DePriest, senior vice president and head of Boston operations. “DPS has evolved from its process engineering roots to deliver services across the engineering and construction value chain, including feasibility studies, architecture, procurement, construction management, CQV, and client-side technical services. With demand at an all-time high, our timely office expansion and addition of new top talent will allow us to better support our clients in the Greater Boston area and beyond.
“The DPS Boston office is the largest project center serving this industry in the Northeast and that offers unique benefits to our clients they cannot find with other service providers. This recent expansion saw added real estate to accommodate significant growth with the Construction Management and CQV teams as well as continued expansion of design and technical services personnel.”
The Boston office has designed three facilities for clients which have been named category winners of the Facility of the Year Award (FOYA) from the International Society of Pharmaceutical Engineering (ISPE). The CRISPR Therapeutics manufacturing facility in Framingham was recognized as the category winner for innovation in 2022; ElevateBio’s BaseCamp, a state-of-the art cGMP development and manufacturing facility for novel therapeutic technologies, for operational excellence in 2021; and a new clinical development manufacturing facility for Moderna for facility of the future in 2019.
Additional recent projects include a new, 118,000sf late-phase clinical and commercial manufacturing facility at 1414 Massachusetts Avenue in Boxborough for Vibalogics, a global contract development and manufacturing organization (CDMO) and a 88,000sf Good Manufacturing Practice (GMP) viral immunotherapy clinical manufacturing facility for Oncorus on the Innovation Park campus located at 4 Corporate Drive in Andover.